Supercharged immune cells show promise for hard-to-treat leukemia relapse

This study tested a new treatment for children and adults whose acute myeloid leukemia (AML) came back after a stem cell transplant. Researchers took immune cells (NK cells) from the original donor, trained them to become 'memory-like' using cytokines, and gave them back to patients along with standard donor lymphocyte infusions. The goal was to boost the immune system's ability to fight the leukemia without causing severe side effects like graft-versus-host disease. The trial enrolled 62 participants and focused on safety and feasibility.